Allergan Announces FDA Approval of Updated Label for New Dosing Regimen for DALVANCE® (dalbavancin)
- Single-Dose Option Approved for Adult Patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
Another $1 per share for those of us who held Durata before it was acquired. Another $3 per share was possible depending on the sales totals for Dalvance. But I never saw any specific numbers mentioned.